Stanisic Danielle I, Good Michael F
Glycomics Institute, Griffith University, Gold Coast, QLD, Australia.
Methods Mol Biol. 2013;923:535-47. doi: 10.1007/978-1-62703-026-7_37.
An effective malaria vaccine remains an important priority for the millions of people living in malaria endemic regions. Subambitious goals for the development of a vaccine have been set, which aim to achieve a licensed first-generation P. falciparum malaria vaccine with more than 50% protective efficacy against severe disease and death, lasting for at least 1 year by 2015. These goals were set in the context of a subunit vaccine. However, a whole-parasite vaccine might be expected to induce substantially superior protection. Our group has been focusing on low dose blood-stage parasites as a valid vaccine approach, and we present here the relevant methodology for this.
对于生活在疟疾流行地区的数百万人而言，一种有效的疟疾疫苗仍然是一项重要的优先事项。已经设定了疫苗开发的适度目标，旨在到2015年获得一种许可的第一代恶性疟原虫疟疾疫苗，该疫苗对严重疾病和死亡的保护效力超过50%，且持续时间至少为1年。这些目标是在亚单位疫苗的背景下设定的。然而，全寄生虫疫苗可能会诱导出实质上更好的保护效果。我们团队一直专注于将低剂量血液阶段寄生虫作为一种有效的疫苗方法，在此我们展示相关的方法。
